Nephrology

1-16 of 21

• 

  RestartResume

  The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis

  RestartResume

  The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis

  MinuteCE®

  The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis

  Richard Lafayette, MD, FACP

  1.00 program credit

  • 

    

    Richard Lafayette, MD, FACP

  1.00 program credit

• 

  RestartResume

  Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN

  RestartResume

  Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN

  MinuteCE®

  Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN

  Richard Lafayette, MD, FACP; Suzuki Yusuke, MD, PhD

  1.00 program credit

  • 

    

    Richard Lafayette, MD, FACP

  • 

    

    Suzuki Yusuke, MD, PhD

  1.00 program credit

• 

  RestartResume

  Mechanism-Based Targeting: Why APRIL Matters in IgAN

  RestartResume

  Mechanism-Based Targeting: Why APRIL Matters in IgAN

  MinuteCE®

  Mechanism-Based Targeting: Why APRIL Matters in IgAN

  Suzuki Yusuke, MD, PhD; Dana Rizk, MD

  1.00 program credit

  • 

    

    Suzuki Yusuke, MD, PhD

  • 

    

    Dana Rizk, MD

  1.00 program credit

• 

  RestartResume

  IgAN SOC: Strengths and Limits

  RestartResume

  IgAN SOC: Strengths and Limits

  MinuteCE®

  IgAN SOC: Strengths and Limits

  Dana Rizk, MD; Suzuki Yusuke, MD, PhD

  1.00 program credit

  • 

    

    Dana Rizk, MD

  • 

    

    Suzuki Yusuke, MD, PhD

  1.00 program credit

• 

  RestartResume

  Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach

  RestartResume

  Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach

  MinuteCE®

  Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach

  Richard Lafayette, MD, FACP; Suzuki Yusuke, MD, PhD

  1.00 program credit

  • 

    

    Richard Lafayette, MD, FACP

  • 

    

    Suzuki Yusuke, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN

  Richard Lafayette, MD, FACP; Dana Rizk, MD

  1.00 credit 9 episodes

  • 

    

    Richard Lafayette, MD, FACP

  • 

    

    Dana Rizk, MD

  • 

    

    Hong Zhang

  • 

    

    Suzuki Yusuke, MD, PhD

  1.00 credit 9 episodes

• 

  RestartResume

  Emerging Therapies in IgAN: Who Could Benefit the Most?

  RestartResume

  Emerging Therapies in IgAN: Who Could Benefit the Most?

  MinuteCE®

  Emerging Therapies in IgAN: Who Could Benefit the Most?

  Richard Lafayette, MD, FACP; Hong Zhang

  1.00 program credit

  • 

    

    Richard Lafayette, MD, FACP

  • 

    

    Hong Zhang

  1.00 program credit

• 

  RestartResume

  APRIL Uncovered: An Upstream Driver in IgAN

  RestartResume

  APRIL Uncovered: An Upstream Driver in IgAN

  MinuteCE®

  APRIL Uncovered: An Upstream Driver in IgAN

  Dana Rizk, MD; Hong Zhang

  1.00 program credit

  • 

    

    Dana Rizk, MD

  • 

    

    Hong Zhang

  1.00 program credit

• 

  RestartResume

  Emerging Evidence: IgAN Disease-Modifying Agents

  RestartResume

  Emerging Evidence: IgAN Disease-Modifying Agents

  MinuteCE®

  Emerging Evidence: IgAN Disease-Modifying Agents

  Richard Lafayette, MD, FACP; Hong Zhang

  1.00 program credit

  • 

    

    Richard Lafayette, MD, FACP

  • 

    

    Hong Zhang

  1.00 program credit

• 

  RestartResume

  Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN

  RestartResume

  Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN

  MinuteCE®

  Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN

  Hong Zhang

  1.00 program credit

  • 

    

    Hong Zhang

  1.00 program credit

• 

  RestartResume

  Should We Look for Gout in the Cardiology Clinic?

  RestartResume

  Should We Look for Gout in the Cardiology Clinic?

  MinuteCE®

  Should We Look for Gout in the Cardiology Clinic?

  Richard Johnson, MD; Brittany Weber, MD, PhD

  • 

    

    Richard Johnson, MD

  • 

    

    Brittany Weber, MD, PhD

• 

  RestartResume

  Is Managing Gout in the Nephrology Clinic a Challenge?

  RestartResume

  Is Managing Gout in the Nephrology Clinic a Challenge?

  MinuteCE®

  Is Managing Gout in the Nephrology Clinic a Challenge?

  Richard Johnson, MD; Abdul Abdellatif, MD, FASN

  • 

    

    Richard Johnson, MD

  • 

    

    Abdul Abdellatif, MD, FASN

• 

  RestartResume

  Treat or Refer: Who Is Responsible for Managing Gout?

  RestartResume

  Treat or Refer: Who Is Responsible for Managing Gout?

  MinuteCE®

  Treat or Refer: Who Is Responsible for Managing Gout?

  John K. Botson, MD, RPh; Abdul Abdellatif, MD, FASN

  • 

    

    John K. Botson, MD, RPh

  • 

    

    Abdul Abdellatif, MD, FASN

• 

  RestartResume

  What Are the Emerging Therapies for Managing Gout?

  RestartResume

  What Are the Emerging Therapies for Managing Gout?

  MinuteCE®

  What Are the Emerging Therapies for Managing Gout?

  Richard Johnson, MD; John K. Botson, MD, RPh

  • 

    

    Richard Johnson, MD

  • 

    

    John K. Botson, MD, RPh

• 

  RestartResume

  Center of the Target: Which Patients Are Most Likely to Develop Gout? 

  RestartResume

  Center of the Target: Which Patients Are Most Likely to Develop Gout? 

  MinuteCE®

  Center of the Target: Which Patients Are Most Likely to Develop Gout? 

  Richard Johnson, MD; Abdul Abdellatif, MD, FASN

  • 

    

    Richard Johnson, MD

  • 

    

    Abdul Abdellatif, MD, FASN

• 

  RestartResume

  What’s New About Gout? Nephrology Perspective

  RestartResume

  What’s New About Gout? Nephrology Perspective

  MinuteCE®

  What’s New About Gout? Nephrology Perspective

  Abdul Abdellatif, MD, FASN; Richard Johnson, MD

  • 

    

    Abdul Abdellatif, MD, FASN

  • 

    

    Richard Johnson, MD

• Prev
• 1
• 2
• Next